Research programme: PARP inhibitors - Pfizer

Drug Profile

Research programme: PARP inhibitors - Pfizer

Alternative Names: AG-14361; AG-14447; HYDAMTIQ; Rucaparib - Pfizer; TBI-361

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cancer Research Technology
  • Developer GVK BIO; Ono Pharmaceutical; Pfizer
  • Class 3-ring heterocyclic compounds; Azulenes; Benzodiazepines; Isoquinolines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer; Cerebral ischaemia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cerebral-ischaemia in Unknown
  • 31 Mar 2011 Preclinical trials in Cerebral ischaemia (unspecified route)
  • 31 Mar 2011 Pharmacokinetics data from an In vitro study presented at the 241st American Chemical Society National Meeting (241st-ACS-2011)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top